A single 0.25 mg dose of Wegovy (semaglutide) stays in your body for roughly five weeks. That number surprises most people, especially given how small the starting dose is, but it follows directly from semaglutide’s unusually long half-life of about seven days. The drug was engineered to linger, which is what makes once-weekly dosing possible in the first place.
Why Five Weeks From a Single Dose
Semaglutide was designed to bind tightly to a blood protein called albumin, which shields it from being broken down quickly. The result is a half-life of roughly six to seven days for the injectable form used in Wegovy.1Scientific Reports. Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes That means about half the drug is still circulating one week after your injection. After two weeks, roughly a quarter remains. After three weeks, an eighth. The general pharmacology rule of thumb is that it takes around five half-lives for a drug to drop to negligible levels, and five times seven days is 35 days. So even though 0.25 mg is the lowest Wegovy dose, it takes about five weeks from your last injection for the drug to be functionally gone.
This long residence time is actually the whole engineering point. Earlier drugs in the same class had half-lives measured in hours, requiring daily or even twice-daily injections.1Scientific Reports. Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes Semaglutide’s predictable, slow-clearing profile is what allows once-weekly dosing without the drug levels swinging wildly between shots.2PubMed Central. Clinical Pharmacokinetics of Semaglutide: A Systematic Review
Does a Lower Dose Clear Faster?
This is the most common misconception around the 0.25 mg question. People assume that because the dose is smaller, it should leave the body sooner. It does not. The half-life stays the same regardless of dose. What changes is the absolute amount of drug at each time point. If you took 0.25 mg, after one half-life you have about 0.125 mg left. If you took the full maintenance dose of 2.4 mg, after one half-life you have about 1.2 mg left. Both took the same seven days to drop by half, but the person on the higher dose still has far more semaglutide circulating at every stage.
The practical takeaway: you will reach undetectable levels slightly sooner on 0.25 mg than on 2.4 mg simply because there was less drug to begin with, but “slightly sooner” means a matter of days, not weeks. Both doses follow the same exponential decline. If your doctor or surgeon asks how long semaglutide will be in your system, the answer is about five weeks from your last injection at any dose.
Steady State and the Dose Escalation Schedule
If you are taking Wegovy on the standard weekly schedule rather than asking about a single dose, there is an additional concept to understand. With repeated weekly injections, each new dose stacks on top of what is still circulating from previous doses. Over the course of about four to five weeks, the drug reaches what pharmacologists call steady state, where the amount entering your body each week roughly equals the amount being cleared.
At steady state on 0.25 mg weekly, your circulating semaglutide levels are higher than they were after the first injection alone. This is by design. The Wegovy dose escalation schedule starts you at 0.25 mg for four weeks, then bumps up to 0.5 mg, then 1.0 mg, 1.7 mg, and finally 2.4 mg, with each step lasting four weeks. That four-week window at each dose level is not arbitrary. It gives the drug time to approach steady state at the current dose before you move to a higher one, which helps your body adjust and reduces the severity of gastrointestinal side effects like nausea.
If you stop during the 0.25 mg phase, your steady-state levels are lower than someone stopping at 2.4 mg, and the drug will drop below measurable thresholds a bit sooner. But the general five-week clearance window still applies as a reasonable estimate.
What You Might Feel as the Drug Leaves
Because semaglutide clears so slowly, the transition off the drug is gradual rather than abrupt. People who stop Wegovy at any dose typically do not experience a sudden “withdrawal” in the way you might with faster-acting medications. Instead, what happens over those five weeks is a slow return of the appetite signals the drug was suppressing.
Semaglutide works by mimicking a gut hormone called GLP-1, which slows stomach emptying and acts on appetite centers in the brain. As drug levels taper, stomach emptying speeds back up, hunger cues return, and the feeling of prolonged fullness after meals gradually fades. Most people stopping from the 0.25 mg dose notice less dramatic appetite rebound than those stopping from higher doses, simply because the appetite suppression was milder at 0.25 mg to begin with.
That said, some side effects can also linger during the washout period. If you experienced nausea, constipation, or other GI issues on 0.25 mg, those symptoms generally improve over the first two to three weeks after your last injection as drug levels fall below the threshold that was triggering them. The timeline is not identical for everyone, but the slow decline means symptoms tend to taper off rather than vanish overnight.
Why Surgeons and Anesthesiologists Care
One of the most practical reasons people ask about semaglutide clearance is an upcoming surgery. The concern is not about the drug interacting with anesthesia directly but about semaglutide’s effect on gastric emptying. Because the drug slows how quickly food moves through your stomach, there is a higher risk that food or liquid is still sitting in the stomach when you go under general anesthesia. If stomach contents are aspirated into the lungs during intubation, it can cause a serious complication called aspiration pneumonia.
Several anesthesiology societies now recommend stopping GLP-1 medications before elective procedures that involve sedation. The exact recommendation varies, but a common guideline is to skip Wegovy for at least one to two weeks before surgery, and some institutions use longer windows. Because the drug’s half-life means it is still meaningfully active well after the last dose, simply skipping one weekly injection does not guarantee your stomach is emptying at a normal rate. If you are on the 0.25 mg dose, the residual gastric-slowing effect is milder than on higher doses, but most anesthesiologists apply the same precautionary timeline regardless of dose.
If you are scheduled for a procedure and are in the early dose-escalation phase of Wegovy, let your surgical team know. Even at 0.25 mg, the drug’s slow clearance means it will still be present and pharmacologically active for weeks after your last injection.
Liver and Kidney Function
People with liver disease sometimes worry that impaired organ function will cause the drug to hang around even longer. Studies of semaglutide in people with various degrees of liver impairment have found that the drug’s half-life does not change in a clinically meaningful way. In one study comparing people with normal liver function to those with mild, moderate, or severe impairment, the half-life ranged from about 142 to 156 hours across all groups, and overall drug exposure appeared similar regardless of liver function status.3Journal of Clinical Pharmacology. Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment That study examined oral semaglutide rather than the injectable form, and the oral version has a slightly shorter half-life than injectable Wegovy, but the key finding holds: liver impairment did not meaningfully slow clearance.
Similar data exist for kidney impairment. Semaglutide is primarily broken down through general protein degradation in the body rather than being filtered through the kidneys or metabolized by the liver in the way many other drugs are. This unusual clearance route is one reason the half-life stays so consistent across different patient populations. For most people, the five-week estimate is reliable regardless of whether your liver or kidneys are working perfectly.
Injectable Versus Oral Semaglutide
It is worth clarifying which form of semaglutide we are talking about, because the question specifically names Wegovy, which is the injectable (subcutaneous) version used for weight management. There is also an oral semaglutide tablet marketed under different brand names for type 2 diabetes. The two forms share the same active molecule but have different pharmacokinetic profiles.
Injectable semaglutide has a half-life of about seven days. Oral semaglutide has a half-life in the range of about six to six and a half days based on clinical pharmacokinetic data.3Journal of Clinical Pharmacology. Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment The difference is modest, and both versions take weeks to fully clear. But because the oral form has lower bioavailability (meaning less of the swallowed dose reaches the bloodstream compared to what gets injected), the peak drug levels and the time to reach those peaks differ between the two. If you are switching between oral and injectable forms, or if a healthcare provider asks which version you have been taking, the distinction matters for estimating your clearance timeline.
Drug Testing and Detection
Another reason people wonder about clearance is concern over drug testing. Standard workplace drug panels do not test for semaglutide. Those panels screen for drugs of abuse and their metabolites, and GLP-1 receptor agonists are not among them. You will not fail a urine drug screen because you took Wegovy.
There are specialized assays that can detect semaglutide in blood, and anti-doping organizations in competitive sports have added GLP-1 receptor agonists to their monitoring programs. If you are a competitive athlete subject to anti-doping testing, semaglutide could theoretically be detected for the full duration of its clearance window, which, as discussed, stretches to about five weeks after the last dose. At the 0.25 mg dose the circulating concentrations are low, but modern assays are sensitive enough to pick up very small amounts. If this applies to you, disclose your prescription to the relevant sporting authority rather than trying to time your last injection around a testing schedule.
Weight Regain After Stopping at 0.25 mg
Many people starting Wegovy at 0.25 mg are in the first month of treatment and have not yet experienced the full weight-loss effect of the drug. The 0.25 mg dose is a tolerability dose, designed to let your body adjust before escalating. Weight loss at this dose is typically modest. If you stop at this early stage, the amount of weight to “regain” is usually small, and the appetite rebound is less pronounced than it would be after months at a higher maintenance dose.
The clinical trials that documented significant weight regain after stopping semaglutide were studying participants who had been on the full 2.4 mg dose for extended periods. Those participants had experienced substantial weight loss, and their bodies had adapted to the drug’s effects on hunger, satiety, and metabolic rate. Stopping after just a few weeks at 0.25 mg is a very different physiological situation. Your appetite-regulation systems have not had time to deeply recalibrate around the drug’s presence, so the rebound is typically gentler.
That said, stopping early also means you have not gotten the drug’s full therapeutic benefit. If you are discontinuing because of side effects at 0.25 mg, it is worth discussing with your prescriber whether the side effects are likely to persist or whether they tend to resolve as your body adjusts. Many of the GI symptoms people experience during the first few weeks of Wegovy improve with continued use, which is one reason the dose-escalation schedule exists.
How Semaglutide Compares to Older GLP-1 Drugs
The question of how long a drug stays in your system is partly a question about the drug class it belongs to. Semaglutide is a GLP-1 receptor agonist, and its half-life represents a dramatic increase over earlier drugs in this category. Exenatide, one of the first approved GLP-1 drugs, had a half-life of only about 2.4 hours, meaning it cleared from the body within a day. Liraglutide extended that to roughly 12 hours. Dulaglutide pushed it further to about 110 hours, or roughly four and a half days. Semaglutide’s six-to-seven-day half-life was a deliberate leap forward, enabling true once-weekly dosing with stable blood levels throughout the week.1Scientific Reports. Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes
If you previously took liraglutide (marketed for weight management under a different brand name), you may remember that its effects wore off within a day of missing a dose. Semaglutide is nothing like that. Missing a single weekly Wegovy injection barely dents your circulating drug levels because there is so much residual drug from previous weeks. This long tail is a benefit for adherence but a consideration for anyone who needs the drug out of their system quickly. Unlike liraglutide, you cannot simply stop semaglutide on a Monday and expect to be clear by Wednesday.
Adolescents and Clearance
Wegovy has been studied in adolescents for obesity treatment, and pharmacokinetic modeling from those trials confirms that the drug’s behavior in teenagers is broadly similar to what is seen in adults.4Diabetes, Obesity and Metabolism. Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach The half-life does not appear to be dramatically different in younger patients, so the five-week clearance estimate applies to adolescents as well. Body weight and body composition can influence how a drug distributes in tissue, and adolescents may have different proportions of lean mass and fat mass compared to adults, but these differences have not been shown to meaningfully shorten or lengthen semaglutide’s time in the body.
If you are a parent of a teenager on Wegovy and need to plan around the drug’s clearance for a medical procedure or other reason, the same general timeline holds. Consult the prescribing physician for guidance specific to your child’s situation, but do not assume faster clearance just because of younger age.